We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 17, 2021

Efficacy and Safety of Revacept in Patients Undergoing Elective PCI for Stable Ischemic Heart Disease

JAMA Cardiology


Additional Info

JAMA Cardiology
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-Blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial
JAMA Cardiol 2021 Mar 31;[EPub Ahead of Print], K Mayer, R Hein-Rothweiler, S Schüpke, M Janisch, I Bernlochner, G Ndrepepa, D Sibbing, T Gori, O Borst, S Holdenrieder, D Kupka, T Petzold, C Bradaric, R Okrojek, DM Leistner, TD Trippel, T Münzel, U Landmesser, B Pieske, AM Zeiher, MP Gawaz, A Hapfelmeier, KL Laugwitz, H Schunkert, A Kastrati, S Massberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading